Cardiol Therapeutics (CRDL) Stock Price, News & Analysis

Company Overview

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes. The company is preparing to initiate further Phase 2 trials in patients with heart failure and preserved ejection fraction to explore the potential of CBD-based therapy to reduce hospitalization rates and improve quality of life. In parallel, Cardiol is investigating novel cyclic dinucleotide immunomodulators designed to recalibrate the innate immune response in cardiovascular settings.

Headquartered in Toronto, Canada, Cardiol Therapeutics operates multiple clinical and research collaborations across North America and Europe. Founded in 2017 and rebranded in 2019 after acquiring its core CBD assets, the company is led by Executive Chairman Peter Hamilton, a seasoned life-science executive, alongside a management team with deep expertise in drug development, regulatory affairs, and cardiovascular research. Cardiol’s strategy emphasizes translational science and collaborative clinical programs to address critical unmet needs in heart disease.

Key Stats

• Today's Range: $1.07 to $1.10
• 50-Day Range: $0.99 to $1.53
• 52-Week Range: $0.77 to $2.54
• Volume: 176,704 shs
• Average Volume: 411,074 shs
• Market Capitalization: $93.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

Cardiol Therapeutics Stock Analysis - MarketRank™

Cardiol Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 675th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Cardiol Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Cardiol Therapeutics has a consensus price target of $8.00, representing about 647.7% upside from its current price of $1.07.

Amount of Analyst Coverage

Cardiol Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cardiol Therapeutics are expected to grow in the coming year, from ($0.33) to ($0.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cardiol Therapeutics is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cardiol Therapeutics is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cardiol Therapeutics has a P/B Ratio of 4.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.01% of the float of Cardiol Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cardiol Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardiol Therapeutics has recently increased by 28.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardiol Therapeutics does not currently pay a dividend.

Dividend Growth

Cardiol Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.01% of the float of Cardiol Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cardiol Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardiol Therapeutics has recently increased by 28.34%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.50

News Sentiment

Cardiol Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cardiol Therapeutics this week, compared to 1 article on an average week.

Search Interest

22 people have searched for CRDL on MarketBeat in the last 30 days. This is an increase of 69% compared to the previous 30 days.

MarketBeat Follows

24 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.25% of the stock of Cardiol Therapeutics is held by insiders.

Percentage Held by Institutions

Only 12.49% of the stock of Cardiol Therapeutics is held by institutions.

CRDL Stock Analysis - Frequently Asked Questions

How have CRDL shares performed this year?

Cardiol Therapeutics' stock was trading at $1.28 on January 1st, 2025. Since then, CRDL stock has decreased by 16.4% and is now trading at $1.07.

How were Cardiol Therapeutics' earnings last quarter?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) issued its quarterly earnings results on Thursday, August, 14th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04.

Who are Cardiol Therapeutics' major shareholders?

Cardiol Therapeutics' top institutional shareholders include Tejara Capital Ltd (3.95%), AdvisorShares Investments LLC (1.04%), MMCAP International Inc. SPC (0.35%) and PVG Asset Management Corp (0.34%).

How do I buy shares of Cardiol Therapeutics?

Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cardiol Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRDL
• CIK: 1702123
• Web: www.cardiolrx.com
• Phone: (289) 910-0850
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cardiol Therapeutics: $8.00
• High Price Target: $9.00
• Low Price Target: $7.00
• Potential Upside/Downside: +647.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -232.26%
• Return on Assets: -158.19%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 2.46
• Quick Ratio: 2.46

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.22 per share
• Price / Book: 4.86

Miscellaneous

• Outstanding Shares: 85,940,000
• Free Float: 81,431,000
• Market Cap: $91.96 million
• Optionable: Not Optionable
• Beta: 1.03